The EPS miss and lack of revenue/guidance updates are negative signals; traders should monitor the AAN presentations for clinical data that could support future commercial potential of azetukalner, but near-term sentiment may remain pressured.
XENE drugs
XENE drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 7 $57.65entry
- T+1 · 7mo ago −0.19%α −2.73% · $57.54
- T+5 · 7mo ago +2.95%α −2.38% · $59.35
- T+20 · 7mo ago −0.43%α −10.21% · $57.40
- T+60 · 5mo ago +5.74%α −7.53% · $60.96
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals (XENE) reported a Q4 2025 earnings miss with EPS of -$1.31 versus consensus of -$1.20, a 9.4% negative surprise. The company highlighted upcoming Phase 3 X-TOLE2 data presentations at AAN 2026, including long-term efficacy and safety data for azetukalner in focal onset seizures, but provided no revenue or guidance updates.
Key Financial Metrics
Key Facts
- Reported Q4 2025 EPS of -$1.31, missing consensus of -$1.20 by 9.4%
- Reported revenue of $1.0M, in line with consensus
- No revenue or earnings guidance was provided
- Announced five abstracts at AAN 2026, including a Late-breaking Science oral presentation of Phase 3 X-TOLE2 topline results for azetukalner in focal onset seizures
- Presented long-term 48-month data from X-TOLE open-label extension and real-world burden of titration in epilepsy
Financial Impact
EPS miss of 9.4% below expectations, no revenue growth or guidance provided
Risk Factors
- Clinical data from X-TOLE2 may not meet efficacy or safety expectations
- Delayed or failed regulatory approval for azetukalner
- Dilution risk from future capital raises given negative EPS and limited revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269108 |
Track record
19 reports on XENE
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers